More people than ever are entering medical school, and with the number of applicants increasing, it is harder to get in.

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.

Elexacaftor/tezacaftor/ivacaftor use is linked to long-term decreases in chronic respiratory therapies in patients with cystic fibrosis.

Individuals with a history of immune-mediated inflammatory diseases (IMIDs) may have a higher risk for sarcoidosis onset, a Japanese study found.

A pulmonologist is sued after responding to a call from ICU staff to prevent airway collapse in a patient who was ultimately left disabled.

For the fifth consecutive year, the number of American teenagers using drugs and alcohol remains at a historic low.

Abortion will stay legal in Wyoming after the state Supreme Court ruled that abortion bans passed by lawmakers violate the state constitution.

Researchers sought to determine the longer-term effects of intensive blood pressure control in older patients.

Researchers evaluated whether pregnancy complications, early childhood characteristics, and tobacco-related exposures were associated with SARDs.

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

The American Academy of Pediatrics is suing HHS over nearly $12 million in federal funding cuts that it says put children’s health programs at risk.